Osteologix, formerly Nordic Bone opens office in San Francisco, California  

2004.12.15
The Danish biotech company has opened an office in San Francisco, CA, to supplement its existing R&D facilities in Copenhagen, and has also appointed a new MD

Osteologix, formerly Nordic Bone has opened an office in San Francisco, CA, to supplement its existing R&D facility at the Symbion Science Park in Copenhagen, and has also appointed a new managing director, Chuck Casamento. The chairman of the board of directors of Osteologix, Klaus Eldrup-Jørgensen, says the new MD has considerable experience and a contact network in the US pharmaceutical and biotech industry which can improve Osteologix' market opportunities and build the right organisation.

 

Osteologix develops pharmaceutical products for the treatment of metabolic bone diseases such as osteoporosis. In early 2005, the biotech company will initiate human clinical trials to test its leading compound for the prevention and treatment of osteoporosis.

 

The market for treatment of osteoporosis is currently estimated at USD 8 bn (DKK 44.8 bn), and is expected to increase strongly in the coming years due to ageing populations, and a higher percentage receiving treatment. The news is reported by Medicon Valley and on Osteologix website.

 

Link > Osteologix 

 

Link > Medicon Valley 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×